Impact of COVID-19 on functional, cognitive, neuropsychiatric, and health-related outcomes in patients with dementia: A systematic review.

ingentiumby ingentium

In Clinical Literature.

Publication date: Mar 01, 2025

This systematic review analyzes the impact of COVID-19 on dementia patients’ functional, cognitive, neuropsychiatric, and health related outcomes. It hypothesizes that dementia patients infected with SARS-CoV-2experience more pronounced deterioration compared to those who are uninfected. Research from 01/03/2020 to 07/10/2023 was conducted using Medline, Web of Science, and Embase databases, and adhering to PRISMA guidelines and the PICO framework. The study aimed to determine if SARS-CoV-2 infection is associated with worse outcomes in dementia patients. The protocol is registered in PROSPERO (CRD42022352481), and bias was evaluated using the Newcastle-Ottawa Scale. Among 198 studies reviewed, only three met the criteria. Chen et al. (2023) identified higher mortality in SARS-CoV-2-infected dementia patients, while Merla et al. (2023) observed faster cognitive decline in infected individuals with increased hospital admissions. Additionally, Cascini et al. (2022) reported an increased risk of infection and significantly elevated mortality in dementia patients, highlighting comorbidities and antipsychotic medication use as key risk factors. These limited data suggest higher mortality and cognitive decline in dementia patients following COVID-19, underscoring the need for extensive research in this area.

Open Access PDF

Concepts Keywords
Crd42022352481 COVID-19
Dementia Dementia
Medline functioning
Ottawa Mild cognitive impairment
Mortality rate
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
disease MESH dementia
pathway REACTOME SARS-CoV-2 Infection
drug DRUGBANK Methionine
disease MESH cognitive decline
disease MESH infection
disease MESH Inflammation
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH sequels
disease MESH upper respiratory infections
disease MESH influenza
disease MESH pneumonia
disease IDO susceptibility
disease IDO intervention
disease IDO process
disease IDO country
disease MESH comorbidity
disease IDO history
disease MESH death
disease MESH hypernatremia
disease MESH liver dysfunction
disease MESH hypoalbuminemia
disease MESH morbidity
disease MESH delirium
disease MESH obesity
disease MESH COPD
disease MESH asthma
pathway KEGG Asthma
disease MESH neoplasm
disease MESH gastric diseases
disease IDO blood
disease MESH anxiety
drug DRUGBANK Ethanol
disease MESH depression
drug DRUGBANK Urea
disease MESH cerebrovascular disease
drug DRUGBANK Oxygen
disease MESH chronic kidney disease
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH inflammatory bowel disease
pathway KEGG Inflammatory bowel disease
disease MESH mental illness
drug DRUGBANK Medical air
disease MESH Coma
disease MESH Respiratory failure
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
disease MESH lifestyle
disease IDO facility
disease MESH Vascular dementia
disease MESH Hypertension
disease MESH dyslipidemia
disease MESH cardiovascular disease
disease MESH Abnormalities
drug DRUGBANK Calcium
disease MESH Frontotemporal Dementia
disease IDO immunodeficiency
disease MESH Congestive heart failure
disease MESH Confusion
disease MESH Frailty
drug DRUGBANK Human vaccinia virus immune globulin
disease MESH Emergency
disease IDO symptom
disease MESH Alzheimer’s disease
disease MESH atrophy
pathway REACTOME Immune System
disease MESH neuroinflammation
disease IDO quality
disease MESH coronavirus infection
disease MESH neurological manifestations
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Guanosine
disease MESH Allergy
pathway REACTOME Innate Immune System
disease MESH critically ill
pathway KEGG Alzheimer disease
disease IDO acute infection
disease MESH Sarcopenia
disease IDO endotoxin

Original Article

(Visited 3 times, 1 visits today)